Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: At present, there are no clinical or laboratory measures that accurately forecast the progression of skin fibrosis and organ involvement in patients with systemic sclerosis (SS c). The goal of this study was to identify skin biomarkers that could be prognostic for the progression of skin fibrosis in patients with early diffuse cutaneous SS c (dc SS c). Methods: We analyzed clinical data and gene expression in skin biopsy samples from 38 placebo‐treated patients, part of the Roche Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (FASSCINATE) phase II study of tocilizumab in SS c. RNA samples were analyzed using nC ounter. A trajectory model based on a modified Rodnan skin thickness score was used to describe 3 skin disease trajectories over time. We examined the association of skin gene expression with skin score trajectory groups, by chi‐square test. Logistic regression was used to examine the prognostic power of each gene identified. Results: We found that placebo‐treated patients with high expression of messenger RNA for CD 14, SERPINE 1, IL 13 RA 1, CTGF, and OSMR at baseline were more likely to have progressive skin score trajectories. We also found that those genes were prognostic for the risk of skin progression and that IL 13 RA 1, OSMR, and SERPINE 1 performed the best. Conclusion: Skin gene expression of biomarkers associated with macrophages (CD 14, IL 13 RA 1) and transforming growth factor β activation (SERPINE 1, CTGF, OSMR) are prognostic for progressive skin disease in patients with dc SS c. These biomarkers may provide guidance in decision‐making about which patients should be considered for aggressive therapies and/or for clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Self-citationMechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153 · cited 2×
“OSM, an IL-6 family cytokine, is produced by a variety of immune cells, including macrophages, neutrophils, and activated T cells (27).”
BackgroundStifano, G., Affandi, A. J., Mathes, A. L., Rice, L. M., Nakerakanti, S., Nazari, B., Lee, J., Christmann, R. B., & Lafyatis, R. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4598 · Cited by 86
Self-citation
Cited by
Skaug, B., Khanna, D., Swindell, W. R., Hinchcliff, M. E., Frech, T. M., Steen, V. D., Hant, F. N., Gordon, J. K., Shah, A. A., Zhu, L., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215894 · Cited by 179
“Similarly, transcripts recently described as predictive of mRSS progression 21 based on samples collected in a phase II study of tocilizumab did not significantly predict postbiopsy mRSS change in this cohort (online supplementary figure 5).”
Self-citationOncostatin M and its role in fibrosis
Stawski, L., & Trojanowska, M. (2019) · Connective Tissue Research · doi:10.1080/03008207.2018.1500558 · Cited by 86
“relates with progression of the skin disease in patients with dcSSc (117).”
BackgroundImmune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Self-citation
Metadata
- Authors
- Stifano, G., Sornasse, T., Rice, L. M., Na, L., Chen‐Harris, H., Khanna, D., Jahreis, A., Zhang, Y., Siegel, J., & Lafyatis, R.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2018-05-28
- Volume
- 70
- Issue
- 6
- Pages
- 912-919
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2807240358
- Cited by
- 62
- References
- 3
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.